2023
DOI: 10.1016/j.ymgme.2023.107712
|View full text |Cite
|
Sign up to set email alerts
|

DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia

Joseph P. Dewulf,
Nathalie Chevalier,
Sandrine Marie
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…Almost all 1,5-AG excreted in urine is reabsorbed in the renal tubules by specific sodium-glucose cotransporter 4 or specific sodium-glucose cotransporter 5 (SGLT4 or SGLT5), and this process ( 4 ) is competitively inhibited by glucose since 1,5-AG and glucose share the transporter protein ( Figure 2 ). Previous research had suggested that SGLT4 is the renal transporter for 1,5-AG, but more recently it has been demonstrated that 1,5-AG is transported by SGLT5, while mannose is transformed by SGTL4 ( 5 , 6 ). Nevertheless, there could be some optional bias because these studies are focused on patients with neutropenia.…”
Section: Overview Of 15-agmentioning
confidence: 99%
“…Almost all 1,5-AG excreted in urine is reabsorbed in the renal tubules by specific sodium-glucose cotransporter 4 or specific sodium-glucose cotransporter 5 (SGLT4 or SGLT5), and this process ( 4 ) is competitively inhibited by glucose since 1,5-AG and glucose share the transporter protein ( Figure 2 ). Previous research had suggested that SGLT4 is the renal transporter for 1,5-AG, but more recently it has been demonstrated that 1,5-AG is transported by SGLT5, while mannose is transformed by SGTL4 ( 5 , 6 ). Nevertheless, there could be some optional bias because these studies are focused on patients with neutropenia.…”
Section: Overview Of 15-agmentioning
confidence: 99%